Edap Tms SA (NASDAQ:EDAP)

3.15
Delayed Data
As of May 22
 -0.08 / -2.48%
Today’s Change
1.15
Today|||52-Week Range
6.05
+35.19%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$78.6M

Company Description

EDAP TMS SA develops, produces and markets minimally invasive medical devices for urological diseases. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. In March 2013, the company introduced a new innovative HIFU device, the Focal One dedicated to focal therapy of prostate cancer. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Contact Information

EDAP TMS SA
Parc d'Activités la Poudrette-Lamart
Vaulx-en-Velin Rhone-alpes 69120
P:(347) 215-3150
Investor Relations:
(347) 826-4046

Employees

Shareholders

Other institutional6.49%
Mutual fund holders4.48%
Individual stakeholders--

Top Executives

Marc OczachowskiChief Executive Officer
Eric SoyerChief Financial Officer
Blandine ConfortHead-Investor Relations & Legal Affairs

To view my watchlist

Not a member yet?

Sign up now for a free account